Congress is currently deliberating a bill that could substantially impact patent law, potentially leading to more costly drugs and delayed market entry for generic medications. The Medication Affordability and Patent Integrity Act is scheduled for review by the Senate Committee on Health, Education, Labor and Pensions in mid-September.
The proposed legislation would require pharmaceutical companies to submit detailed and technical information from clinical trials to the U.S. Patent and Trademark Office (USPTO) and certify that this information aligns with what is provided to the Food and Drug Administration (FDA). While seemingly straightforward, this could cause several unintended issues.
Firstly, the new bill gives the Department of Commerce the discretion to apply the law as it “determines appropriate,” potentially injecting political considerations into the patent application process. This variability could lead to inconsistent application of the law across different administrations.
Secondly, the legislation would likely make patent litigation more costly. Patent holders may need to defend against allegations of failing to disclose pertinent information to the USPTO or inconsistencies in submitted data, which would require courts to parse through scientific and technical documentation.
Moreover, there is concern that the bill could discourage the disclosure of critical information to the FDA. Applicants may fear that confidential FDA data might inadvertently become public during the USPTO application process, jeopardizing trade secrets.
Additionally, the bill may overwhelm the USPTO with data submissions, causing delays in the patent examination process. This could subsequently extend the duration of patents and postpone the availability of generic drugs. While enhancements in the patent examination process, such as additional review time and clearer guidelines, are necessary, the proposed mandates largely reflect current practices where relevant information must already be shared between the FDA and USPTO.
Ultimately, while the aim of the bill is to make drugs cheaper and more accessible, experts argue that it could achieve the opposite by destabilizing patent law and leading to higher drug prices. More about the implications of this bill can be read here.